UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 234

Sortiert nach

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Blood cancer journal (New York), 2024-03, Vol.14 (1), p.40-40, Article 40

2024

Volltextzugriff (PDF)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

Blood cancer journal (New York), 2024-02, Vol.14 (1), p.24-24, Article 24

2024

Volltextzugriff (PDF)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1

HemaSphere, 2023-08, Vol.7 (S3), p.e646904e-n/a

2023

Volltextzugriff (PDF)

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8036-8036

2023

Volltextzugriff (PDF)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

HemaSphere, 2023-05, Vol.7 (S2), p.26-27

2023

Volltextzugriff (PDF)

Zero-Added-Loss Entangled-Photon Multiplexing for Ground- and Space-Based Quantum Networks

Physical review applied, 2023-05, Vol.19 (5), Article 054029

2023

Volltextzugriff (PDF)

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.4418-4419

2022

Volltextzugriff (PDF)

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO‐ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION

HemaSphere, 2022-06, Vol.6, p.71-72

2022

Volltextzugriff (PDF)

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

Advances in therapy, 2021-02, Vol.38 (2), p.1328-1341

2021

Volltextzugriff (PDF)

The α2 Na+/K+-ATPase isoform mediates LPS-induced neuroinflammation

Scientific reports, 2020-08, Vol.10 (1), Article 14180

2020

Volltextzugriff (PDF)

Phase 3, open-label, non-inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba

BRITISH JOURNAL OF HAEMATOLOGY, 2020, Vol.189, p.22

2020

Volltextzugriff (PDF)

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

BLOOD, 2019-11, Vol.134 (Supplement_1), p.3151-3151

2019

Volltextzugriff (PDF)

Update: Clinical imaging of cartilage-part 2 : Aspects helpul in daily clinical practice

Radiologe, 2019-08, Vol.59 (8), p.700-709

2019

Volltextzugriff (PDF)

Update: clinical imaging of cartilage-part 1 : Technical aspects

Radiologe, 2019-08, Vol.59 (8), p.692-699

2019

Volltextzugriff (PDF)

Update: Klinische Knorpelbildgebung – Teil 2: In der Klinik hilfreiche Aspekte

Radiologe, 2019-08, Vol.59 (8), p.700-709

2019

Volltextzugriff (PDF)

Update: Klinische Knorpelbildgebung – Teil 1: Technische Aspekte

Radiologe, 2019-08, Vol.59 (8), p.692-699

2019

Volltextzugriff (PDF)

S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

HemaSphere, 2019-06, Vol.3 (S1), p.364-n/a

2019

Volltextzugriff (PDF)

Update: Klinische Knorpelbildgebung – Teil 2

Radiologe, 2019-01, Vol.59 (8), p.700-709

2019

Volltextzugriff (PDF)

1 – 25 von 234

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(159)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(101)
Humans
(97)
Life Sciences & Biomedicine
(85)
Biochemistry & Molecular Biology
(26)
Biological And Medical Sciences
(25)
Oncology
(22)
Male
(21)
Animals
(19)
Multiple Myeloma
(16)
Medical Sciences
(15)
Triglycerides - Blood
(15)
Adult
(14)
Hematology
(14)
Biochemical Research Methods
(13)
Cholesterol - Blood
(13)
Physical Sciences
(13)
Technology
(12)
Fundamental And Applied Biological Sciences. Psychology
(11)
Middle Aged
(11)
Multiple Myeloma - Genetics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

P42 HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL‐1

Zero-Added-Loss Entangled-Photon Multiplexing for Ground- and Space-Based Quantum Networks

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO‐ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

The α2 Na+/K+-ATPase isoform mediates LPS-induced neuroinflammation

Phase 3, open-label, non-inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Update: Clinical imaging of cartilage-part 2 : Aspects helpul in daily clinical practice

Update: clinical imaging of cartilage-part 1 : Technical aspects

Update: Klinische Knorpelbildgebung – Teil 2: In der Klinik hilfreiche Aspekte

Update: Klinische Knorpelbildgebung – Teil 1: Technische Aspekte

S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Update: Klinische Knorpelbildgebung – Teil 2

Aktive Filter

Suchergebnisse filtern